Sotatercept - Acceleron Pharma/Celgene Corporation

Drug Profile

Sotatercept - Acceleron Pharma/Celgene Corporation

Alternative Names: ACE-011; ACTRIIA-Fc; RAP-011

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acceleron Pharma
  • Developer Acceleron Pharma; Celgene Corporation; Indiana University; North Shore-Long Island Jewish Health System; University of Texas M. D. Anderson Cancer Center
  • Class Osteoporosis therapies; Recombinant fusion proteins
  • Mechanism of Action Activin inhibitors; Bone resorption factor inhibitors; Haemoglobin stimulants; Osteoblast inhibitors; Osteoclast stimulants; Osteogenesis stimulants; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Beta-thalassaemia; Anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anaemia; Beta-thalassaemia; Myelofibrosis; Pulmonary arterial hypertension; Renal osteodystrophy; Vascular calcification
  • Phase I/II Diamond-Blackfan syndrome
  • No development reported Cancer metastases; Chemotherapy-induced anaemia; Postmenopausal osteoporosis; Sickle cell anaemia

Most Recent Events

  • 22 May 2018 Phase-II clinical trials in Pulmonary arterial hypertension in USA (Parenteral) (NCT03496207)
  • 27 Feb 2018 Acceleron Pharma files for patent protection with USPTO for method of treatment of pulmonary arterial hypertension in USA
  • 14 Nov 2017 Pharmacodynamics data from a preclinical trial in Pulmonary arterial hypertension released by Acceleron Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top